![Frontiers | Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity Frontiers | Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity](https://www.frontiersin.org/files/Articles/1004044/fendo-13-1004044-HTML/image_m/fendo-13-1004044-g002.jpg)
Frontiers | Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
![Efficacy and safety of three dose-escalation algorithms of tirzepatide, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes - Media Centre | EASD Efficacy and safety of three dose-escalation algorithms of tirzepatide, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes - Media Centre | EASD](https://d2t0unnjxes6lt.cloudfront.net/data/easd/data/talks/1006_668326/Slide3.jpg)
Efficacy and safety of three dose-escalation algorithms of tirzepatide, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes - Media Centre | EASD
![Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes – touchENDOCRINOLOGY Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes – touchENDOCRINOLOGY](https://www.touchendocrinology.com/wp-content/uploads/sites/5/2022/06/Fig-3.png)
Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes – touchENDOCRINOLOGY
Kilogram-Scale GMP Manufacture of Tirzepatide Using a Hybrid SPPS/LPPS Approach with Continuous Manufacturing | Organic Process Research & Development
![The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect | Cardiovascular Diabetology | Full Text The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect | Cardiovascular Diabetology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12933-021-01412-5/MediaObjects/12933_2021_1412_Fig1_HTML.png)
The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect | Cardiovascular Diabetology | Full Text
![Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors | Nature Communications Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors | Nature Communications](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41467-022-28683-0/MediaObjects/41467_2022_28683_Fig7_HTML.png)
Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors | Nature Communications
![Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial - The Lancet Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial - The Lancet](https://www.thelancet.com/cms/attachment/f8796f89-5117-40f3-b350-bca267093e71/gr1.gif)
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial - The Lancet
![Molecules | Free Full-Text | Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review Molecules | Free Full-Text | Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review](https://pub.mdpi-res.com/molecules/molecules-27-04315/article_deploy/html/images/molecules-27-04315-g004.png?1657082309)
Molecules | Free Full-Text | Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review
![tirzepatide | dual GIP/GLP-1 receptor agonist | CAS 2023788-19-2 | Buy LY-3298176; Mounjaro from Supplier InvivoChem tirzepatide | dual GIP/GLP-1 receptor agonist | CAS 2023788-19-2 | Buy LY-3298176; Mounjaro from Supplier InvivoChem](https://www.invivochem.com/Private/g3/M00/08/8A/CgAH513CmumAMgbgAABksQGtNNU759.png)
tirzepatide | dual GIP/GLP-1 receptor agonist | CAS 2023788-19-2 | Buy LY-3298176; Mounjaro from Supplier InvivoChem
![Patrick Holmes 💙 on Twitter: "Tirzepatide. This is a name we are going to hear so much more about. The name for @LillyDiabetes Dual GIP/GLP-1 RA. All post-hoc data from https://t.co/YrQvelF5XF… Points Patrick Holmes 💙 on Twitter: "Tirzepatide. This is a name we are going to hear so much more about. The name for @LillyDiabetes Dual GIP/GLP-1 RA. All post-hoc data from https://t.co/YrQvelF5XF… Points](https://pbs.twimg.com/media/D8lX_TWU8AEZngk.jpg)
Patrick Holmes 💙 on Twitter: "Tirzepatide. This is a name we are going to hear so much more about. The name for @LillyDiabetes Dual GIP/GLP-1 RA. All post-hoc data from https://t.co/YrQvelF5XF… Points
![Molecules | Free Full-Text | Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review Molecules | Free Full-Text | Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review](https://www.mdpi.com/molecules/molecules-27-04315/article_deploy/html/images/molecules-27-04315-g003.png)
Molecules | Free Full-Text | Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review
![The novel dual GIP and GLP-1 receptor agonist, tirzepatide, transiently delays gastric emptying similarly to a selective long-acting GLP-1 receptor agonist - Media Centre | EASD The novel dual GIP and GLP-1 receptor agonist, tirzepatide, transiently delays gastric emptying similarly to a selective long-acting GLP-1 receptor agonist - Media Centre | EASD](https://d2t0unnjxes6lt.cloudfront.net/data/easd/data/talks/1006_668324/Slide3.jpg)
The novel dual GIP and GLP-1 receptor agonist, tirzepatide, transiently delays gastric emptying similarly to a selective long-acting GLP-1 receptor agonist - Media Centre | EASD
![Structural basis for the therapeutic advantage of dual and triple agonists at the human GIP, GLP-1 or GCG receptors | bioRxiv Structural basis for the therapeutic advantage of dual and triple agonists at the human GIP, GLP-1 or GCG receptors | bioRxiv](https://www.biorxiv.org/content/biorxiv/early/2021/07/31/2021.07.29.454286/F7.large.jpg)
Structural basis for the therapeutic advantage of dual and triple agonists at the human GIP, GLP-1 or GCG receptors | bioRxiv
![Kilogram-Scale GMP Manufacture of Tirzepatide Using a Hybrid SPPS/LPPS Approach with Continuous Manufacturing | Organic Process Research & Development Kilogram-Scale GMP Manufacture of Tirzepatide Using a Hybrid SPPS/LPPS Approach with Continuous Manufacturing | Organic Process Research & Development](https://pubs.acs.org/cms/10.1021/acs.oprd.1c00108/asset/images/large/op1c00108_0009.jpeg)
Kilogram-Scale GMP Manufacture of Tirzepatide Using a Hybrid SPPS/LPPS Approach with Continuous Manufacturing | Organic Process Research & Development
![Molecules | Free Full-Text | Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review Molecules | Free Full-Text | Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review](https://www.mdpi.com/molecules/molecules-27-04315/article_deploy/html/images/molecules-27-04315-g002.png)
Molecules | Free Full-Text | Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review
![Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial - The Lancet Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial - The Lancet](https://www.thelancet.com/cms/attachment/63fe4912-d57e-4c87-ad6b-1952000f93e1/gr1_lrg.jpg)
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial - The Lancet
![Structural basis for the therapeutic advantage of dual and triple agonists at the human GIP, GLP-1 or GCG receptors | bioRxiv Structural basis for the therapeutic advantage of dual and triple agonists at the human GIP, GLP-1 or GCG receptors | bioRxiv](https://www.biorxiv.org/content/biorxiv/early/2021/07/31/2021.07.29.454286/F6.large.jpg)
Structural basis for the therapeutic advantage of dual and triple agonists at the human GIP, GLP-1 or GCG receptors | bioRxiv
![Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors | Nature Communications Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors | Nature Communications](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41467-022-28683-0/MediaObjects/41467_2022_28683_Fig1_HTML.png)
Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors | Nature Communications
cardio-met on Twitter: "From mice models GIP only lowers glucose when glucose close to normal (data not shown) In GLP-1 knockout mice Tirzepatide is much better at weight loss compared to semaglutide
![Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors | Nature Communications Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors | Nature Communications](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41467-022-28683-0/MediaObjects/41467_2022_28683_Fig3_HTML.png)